Ozempic Reduces Kidney Disease Progression, Cardiovascular Events by 24%
The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.
In patients with type 2 diabetes and kidney disease, Ozempic (semaglutide) reduced kidney disease progression, major adverse cardiovascular events (MACE) and death by 24%, according to topline results from the FLOW trial. The trial was stopped early on the recommendation from an independent data monitoring committee because an interim analysis found the study met the criteria for efficacy.
In the trial, which enrolled 3,533 people with type 2 diabetes and chronic kidney disease, patients were randomized to receive Ozempic 1.0 mg with placebo or placebo, along with standard of care for kidney disease.
Secondary endpoints — including annual rate of change in eGFR1 and non-fatal myocardial infarction, non-fatal stroke, cardiovascular death — also confirmed the positive impact on slowing kidney disease and cardiovascular events.
Ozempic, which was developed by Novo Nordisk, is available in 0.5 mg, 1.0 mg and 2.0 mg doses. It is a glucagon-like peptide-1 (GLP-1) inhibitor, a class of drugs that work in pancreas to enhance insulin release. The list price for Ozempic 1.0 mg is $935.77 for one pen.
A higher dose of semaglutide is also marketed as Wegovy with a weight loss indication. Wegovy has a list price of $1,349.02 per package, which is a 28-day supply.
Martin Holst Lange
“Approximately 40% of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease,” Martin Holst Lange, executive vice president for Development at Novo Nordisk, said in a press release.
Company officials said that full results will be presented at a conference this year.
This follows the results of a separate trial, SELECT, announced last year. In that trial, the semaglutide product Wegovy 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults who were overweight who had obesity. The trial enrolled 17,604 adults aged 45 years or older with obesity and established cardiovascular disease with no prior history of diabetes. These results were released at the American Heart Association Scientific Session meeting in November 2023.
Novo Nordisk has filed for a label update of Wegovy in both the United States and the Europea Union based on the SELECT study findings, and a decision is expected in 2024
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
